Tentarix Biotherapeutics Launches with $50 Million Series A to Advance Multifunctional Biotherapeutics

San Diego-based Tentarix Biotherapeutics announced the closing of a $50 million Series A investment co-led by Versant Ventures and Samsara BioCapital. The funding will be used to advance the company’s novel platform to generate targeted, multifunctional, conditional biotherapeutics with broad applications.

“The advent of technologies to produce high-precision biologics to engage multiple disease targets represents a major advance,” said President and CEO Paul Grayson, a Venture Partner at Versant Ventures. “This financing allows us to develop multiple programs for oncology and autoimmune disease based on the Tentarix technology platform.”

The goal of Tentarix's novel platform is to generate multifunctional biotherapeutics that can conditionally activate or inhibit specific cell populations. If successful, the platform could potentially be used to activate cancer-killing immune cells without disturbing other immune cells that could have adverse effects.

The company’s lead program is a multifunctional therapeutic with subunits that target the IL2R gamma receptor, the IL2R beta receptor and bind to cell surface proteins on a specific subset of T cells.

Prior companie...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee